Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA), the world’s largest generic drug manufacturer, is seeking acquisitions in Asia in order to boost sales there and expand production, “Bloomberg” reports, quoting two of the company’s senior executives. Teva CFO Eyal Desheh told the J.P. Morgan Healthcare Conference in San Francisco, “A lot of the future growth of the generic industries is going to happen in Asia. The population is very large.” In 2011, Teva acquired a 57% stake in Japan-based Taiyo Pharmaceutical Industry for $460 million in cash.
